Simcere Pharmaceutical Group to Announce 2009 Third Quarter Earnings on Monday, November 16, 2009

Simcere Pharmaceutical Group to Announce 2009 Third Quarter Earnings on
Monday, November 16, 2009

NANJING, China, Nov. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group
(NYSE: SCR), a leading pharmaceutical company specializing in the development,
manufacturing, and marketing of branded generic and proprietary
pharmaceuticals in China, announced today that it intends to release its 2009
third quarter results on Monday, November 16, 2009, before the market opens in
the United States. Simcere's chief executive officer, Jinsheng Ren, and chief
financial officer, Frank Zhigang Zhao, will host an earnings conference call
to discuss the company's 2009 third quarter results on the same day, at 8 a.m.
ET (Monday, November 16, at 9 p.m.Beijing/Hong Kong time).
To access the conference call, please dial:

United States toll-free: +1.800.706.7741
International: +1.617.614.3471
North China toll-free: 10.800.152.1490
South China toll-free: 10.800.130.0399
China toll free / Netcom: 10.800.852.1490
Hong Kong: +852.3002.1672

Please ask to be connected to Q3 2009 Simcere Pharmaceutical Group
Earnings Conference Call and provide the following passcode: 32750293.
Simcere will also broadcast a live audio webcast of the conference call.
The broadcast will be available by visiting the "Investor Relations" section
of the company's web site at http://www.simcere.com .
Following the earnings conference call, an archive of the call will be
available by dialing:

United States toll-free: +1.888.286.8010
International: +1.617.801.6888

The passcode for replay participants is: 77133325.The telephone replay
also will be archived on the "Investor Relations" section of the company's web
site for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading
pharmaceutical company specializing in the development, manufacturing, and
marketing of branded generic and proprietary pharmaceuticals in China. In
recent years, Simcere has been focusing its strategy on the development of
innovative pharmaceuticals and first-to-market generics, and has introduced an
innovative anti-cancer medication Endu, a first-to-market medication Sinofuan,
and first-to-market generics such as Bicun and Anxin. Simcere manufactures and
sells anti-infective medication, anti-cancer medication and stroke management
medication. Simcere concentrates its research and development efforts on the
treatment of diseases with high incidence and/or mortality rates and for which
there is a clear demand for more effective pharmacotherapy such as cancer,
strokes, orthopaedics and infectious diseases. For more information about
Simcere Pharmaceutical Group, please visit http://www.simcere.com .
SOURCE Simcere Pharmaceutical Group

Simcere, ir@simcere.com; or in Nanjing, Frank Zhigang Zhao, Chief Financial
Officer of Simcere Pharmaceutical Group, +86-25-8556-6666 x8818, or in in
Beijing, Ruirui Jiang, +86-10-6566-2256, or in Hong Kong, Joseph Lo Chi-Lun,
+852-3512-5000, or in New York, Kate Tellier, +1-212-333- 3810, all of
Brunswick Group, for Simcere